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Abstract 
Objectives: The objective is to present the antibiotic elution from a locally implanted gentamicin 
containing hydroxyapatite and calcium sulphate bone substitute with an extended follow up of 30 
days.  
We also compare the pharmacokinetics of the ceramic bone substitute with a published study on 
gentamicin containing poly (methyl methacrylate) (PMMA) bone cement used in primary total hip 
arthroplasty.  
Methods: Gentamicin release was measured in the urine for a month and the serum for 4 days in 
10 patients operated for trochanteric hip fractures and 10 patients in uncemented hip revisions. 17 
patients were followed up at one year and 3 patients at 6 months.  
Results and Discussion: The gentamicin concentrations measured in serum were low and 
approximately 100 times less than in urine during the first days, indicating high local concentrations 
at the implant site. The elution from the biphasic bone substitute showed a stronger burst and 
higher gentamicin concentrations for the first week compared to that reported for PMMA used in 
hip arthroplasty. Also, for the bone substitute a complete gentamicin elution was obtained after 30 
days, while for the PMMA cement sub-inhibitory MIC levels of gentamicin were still present in urine 
60 days past surgery. No infections were detected. 
Conclusions: A new biphasic bone substitute containing antibiotics could potentially be used to 
prevent infection in patients treated for trochanteric hip fractures or uncemented hip revisions. The 
gentamicin elution from the bone substitute is efficient with high initial local gentamicin 
concentrations and complete release at 30 days. 
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Introduction 
Local delivery of antibiotics has been shown to 
be effective in preventing infections in total hip 
surgery1. These patients are often old and more prone 
to be affected by infections than younger patients 
groups. The infections cause major suffering 
impacting the quality of life and generally several 
surgeries over years, resulting in high societal costs.  
This study presents a new bone generating 
ceramic material which eludes gentamicin to prevent 
the occurrence of infection while enhancing the bone 
healing. The product (CERAMENT™|G, 
BONESUPPORT AB, Lund, Sweden) was developed 
by adding antibiotics to a clinically well documented 
bone regenerating biphasic ceramic bone graft 
substitute2-5 and it was predicted that the gentamicin 








organisms in order to protect the bone healing.  
This study is an addition to previously short 
term published data6 on the gentamicin elution from 
the biphasic bone substitute CERAMENT™|G. The 
objective of this new study is to present the 
gentamicin elution from the same product in major 
hip surgery over an extended time period, 1 month vs 
1 week, as well as to compare this elution with 
reported release curves from PMMA7.  
Another aim of this study is to show that the 
local concentration of gentamicin would reach 
bactericidal level, while the systemic concentration 
will be well below toxic levels. 
Materials and Methods 
20 patients underwent hip surgery augmented 
with a synthetic bone graft substitute 
(CERAMENT™|G, BONESUPPORT AB, Lund, 
Sweden). 10 patients with trochanteric fracture were 
treated with augmented internal fixation and 10 
patients underwent augmented uncemented hip 
revision. The ceramic material was injected after 
drilling in the distal part of the femoral neck followed 
by insertion of the sliding screw in trochanteric 
fractures. In the uncemented revisions a distal 
anchored stem was used and the ceramic material was 
injected in the unsupported proximal femoral part. 
The patient population were 3 men and 17 women 
with a mean age of 76 years, (±SD 9 years range 
57-90y).  
The synthetic bone graft substitute consisted of 
40wt% hydroxyapatite particles in a calcium sulphate 
matrix and contained 175mg gentamicin per 10 mL.  
None of the patients had systemic gentamicin 
during the study period.  
The patients stayed 7 days at the hospital 
post-operatively, and both urine and blood serum 
samples were collected during this time to analyze the 
gentamicin release from the bone graft substitute. 
Urine was collected daily during the hospital 
stay (7 days) and thereafter approximately every third 
days for a month. During the first 4 days it was 
collected from a urinary catheter and thereafter 
morning urine was collected. The samples were 
homogenized, transferred into two 50 mL tubes and 
kept cool in a refrigerator. 
Blood serum was assessed every hour for the 
first 6h post-op and thereafter every 6h (±1h) until 96h 
post-op (totally 21 samples per patient). A minimum 
of 4 mL of blood was withdrawn at each time-point 
and placed in a 5 mL heparin tube. They were 
centrifuged for 10 min at 2200 x g and the supernatant 
was transferred to two 5 mL polypropylene tubes and 
deep frozen at -80℃ until analysis.  
The gentamicin concentrations in both urine and 
blood serum were analyzed using a validated 
antibody technique (QMS® Gentamicin Assay, 
Indiko™, Thermo Scientific), with a detection limit of 
the gentamicin concentration of 0.2 mg/L. 
Post-op examinations of the patients were 
performed at 3-6 months and at 1 year. The patients 
were followed to detect any complications, to observe 
early loosening of the implants and to study the 
integration of the material.  
The study was approved by the local ethical 
committee at Lithuanian University of Health, 
Kaunas, Lithuania (No. BE-2-43) and written 
informed consent to participate in the study was 
obtained from all participants.  
Results 
The elution of gentamicin 
from the biphasic ceramic bone 
substitute had an initial serum 
peak and then it flattened out 
after the first days to stay at low 
levels for the rest of the sampling 
time (Fig 1). The gentamicin 
concentrations in the serum was 
always well below the maximum 
recommended systemic level of 
12 mg/L.  
In the urine, the gentamicin 
concentrations were initially 
approximately 100 times higher 
than that in serum. The peak 
levels were around 100 mg/L and 
after one week it was still 1 mg/L 
(Fig 2), reflecting high local 
 
Figure 1: Gentamicin concentrations measured in serum. Every ○ represents one measurement. 
 




concentrations at the implantation sites. After the first 
week, the gentamicin concentration in the urine 
decreased and was maintained at levels below 1 
mg/L for the rest of the sampling time. At 
approximately 28 days, all gentamicin had eluted 
from the implants (see dotted line in Fig 2).  
17 patients were followed for 1 year and 3 
patients followed for 6 months; there were no 
loosening of the revised hips seen during this short 
follow-up time and no evidence of infection was 
detected in any of the patients.  
Discussion  
The elution of gentamicin from the ceramic bone 
substitute started with an initial burst which 
decreased mainly during the first week. The elution 
was followed for 30 days with the aim to present an 
extended follow-up of already published data in a 
previous study6. 
The antibiotic concentrations measured in the 
urine was 100 times the serum concentrations for the 
first day, which indicate high local concentrations and 
should allow eradication of any planktonic bacteria 
causing infection and be effective in preventing 
bacterial adherence and biofilm production. High 
local concentrations have also been confirmed and 
presented in an earlier study6 where gentamicin 
concentrations in the wound drainage were measured 
during the first days post-op. 
 
 
Figure 2: Gentamicin concentrations measured in urine. Every ○ represents one measurement. The dotted line represents the trend line. 
 
Figure 3: Gentamicin concentrations measured in urine in patients treated with PMMA cements. Figure re-published from Törholm et al.7 with permission from 
Wolters Kluwer Health, Inc. The line represents the trend line from Fig 2 for comparison. 




Törholm et al.7 stated that there is a relation 
between the antibiotic concentration in the urine and 
the amount of drug available for antimicrobial action 
at the cement-tissue interface, i.e. locally.  
The gentamicin concentration in the urine was 
detectable for up to 30 days (see Fig 2) which indicates 
prolonged drug elution in the patients studied. The 
concentrations decreased following the power 
function [y=43.6x-1.8, R2=0.88] (see dotted line in Fig 2 
and solid line in Fig 3) and it shows that almost all 
gentamicin has been eluted at approximately 28 days. 
Similar data was published in a previous study where 
the analysis was based on in vitro sampling and 
complete elution of gentamicin occurred at 28 days6. 
This should be compared to other antibiotic eluting 
cements, such as PMMA, which entraps the 
antibiotics with a more prolonged release as a 
result7,9-10.  
We did comparison with a study performed by 
Törholm et al.7 who reported gentamicin 
concentrations in urine from patients cemented with 
gentamicin-impregnated PMMA for hip joint 
arthroplasty. The elution of the gentamicin from the 
PMMA cement (Fig 3) may appear similar to that of 
the ceramic bone substitute (Fig 2), with a burst 
release for the first days followed by a rapid decrease. 
However, there are large differences. The burst from 
the ceramic bone substitute is higher with gentamicin 
concentrations close to 100 mg/L for the first two 
days compared to maximum 25 mg/L the first day 
from the PMMA cement. It should also be noted that 
the mean gentamicin implanted per patient in the 
PMMA study7 was 653 mg while 128 mg was reported 
per patient in the bone substitute study6. Hence, 
despite a higher concentration of gentamicin in the 
PMMA, it had a significantly lower burst than 
observed in the bone substitute patients (25mg/L vs 
100mg/L).  
This may be explained by the nature of the 
material and the ability for it to elude the antibiotics. 
The ceramic bone substitute is a porous material, 
containing approximately 30% microporosity, and the 
calcium sulphate component resorbs with time in the 
body2,5. It subsequently eludes the antibiotics from 
both the surface and the bulk which makes it possible 
for it to completely elude all antibiotics without any 
residuals being trapped within it. Gentamicin will not 
bind chemically, nor electrostatically, to 
hydroxyapatite. Thereby, the complete elution of the 
gentamicin will be determined by the resorption of 
the calcium sulphate which normally takes place over 
1-2 months11 but resorption rates as long as 6 months 
have also been reported for similar materials12.  
In a previous study, it was also shown that the 
surface area of the biphasic bone substitute did not 
have any effect on the release rate of the antibiotics6. 
PMMA is a non-resorbing material without 
significant interconnecting porosity, which means 
that the antibiotic elusion is mainly occurring from 
the surface13. It is controlled by the surface area of the 
material and the concentration gradient between the 
material surface and the surrounding tissue, resulting 
in a burst followed by a sustained slow and low 
release7. The gentamicin stays entrapped in the 
PMMA matrix and elutes for years at antibiotic 
concentrations below the therapeutically level9,10, and 
it has been shown that prolonged release at low levels 
may induce bacterial antibiotic resistance14. Other 
studies have confirmed that antibiotic-loaded PMMA 
cement reduces infection in total hip replacement but 
maybe at the price of increasing case specific bacterial 
resistance1,15. Also, severe side effects such as renal 
failure and ototoxicity have been reported with 
prolonged gentamicin release, even at low levels, 
especially if the patient is already suffering from renal 
insufficiency16. It is therefore important to use a 
material which assures an efficient and complete 
elution of the gentamicin within a short period of 
time, i.e. in months. 
In Törholm et al.7, the elution was followed for 
60 days at which the gentamicin concentration still 
was detected at 0.3mg/L. At 2 years, the total amount 
of gentamicin eluted was estimated to be 275 mg 
corresponding to 44% of the total gentamycin amount 
implanted7. 
For the ceramic bone substitute, the gentamicin 
elution was maintained at significantly higher levels 
than for the PMMA cement for the first 10 days, with 
levels dropping from 100mg/L to 1 mg/L over the 
time period compared to from 25mg/L to 1 mg/L for 
the PMMA-cement.  
The initial urine peak concentration in the 
gentamicin containing PMMA was significantly 
shorter and lower despite that 5 times more 
gentamicin was implanted7. But most importantly, 
after 2 months low sub-inhibitory MIC levels of 
gentamicin were still measured (see Fig 3).  
In summary, the gentamicin elution from the 
biphasic ceramic bone substitute presented in this 
study was more efficient than that of PMMA cements 
due to a higher initial release followed by higher local 
concentrations for the first week. Moreover, a 
complete gentamicin elution was obtained for the 
bone substitute with a minimal risk for bacterial 
resistance while for the PMMA sub-inhibitory MIC 
levels of gentamicin were still detectable at 60 days 
and two years after implantation7.  
The number of patients studied was small and 
without comparable group, but there were no 
evidence of infection seen in any of the patients 




during the follow-up time. Other studies performed 
using the same ceramic bone substitute confirm this 
result, reporting very low rate of recurrence in 
relapsing long standing osteomyelitis8.  
No loosening of the implants was observed and 
active integration of the material in the bone healing 
process could be seen17.  
Conclusions 
This study presents a prolonged follow-up of 
gentamicin elution from a biphasic ceramic bone 
substitute used for augmentation of internal fixations 
in trochanteric fractures and of uncemented hip 
revisions. The gentamicin concentrations were 
measured for 30 days and gives evidence for an 
extended efficient antibiotic elution and infection 
prevention than earlier reported6.  
It shows that the urine concentrations of 
gentamicin were approximately 100 times the 
concentration in serum, indicating high local 
concentrations at the implantation site. Compared to 
gentamicin containing PMMA7, the elution was 
initially higher and maintained at a higher level for 
the first week. At 30 days, the elution from the 
biphasic ceramic bone substitute was complete, while 
sub-inhibitory MIC levels of gentamicin were still 
detectable at 60 days for the PMMA cement, with a 
reduced risk of developing bacterial antibiotic 
resistance with the ceramic material.  
Abbreviations 
PMMA: poly (methyl methacrylate); MIC: 
minimum inhibitory concentration.  
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